Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00615186 is registered in ClinicalTrials.gov with Bradmer Pharmaceuticals Inc. as lead sponsor.

NCT NCT00615186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00615186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Study of Neuradiab in Combination With External Beam Radiation and Temozolomide Versus External Beam Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Lead sponsor
Bradmer Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2008
Completion date
December 31, 2013
Enrollment
9 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme